黄燕华, 邢燕飞, 茅敏华. 肺腺癌后再发小细胞肺癌2例报告[J]. 实用临床医药杂志, 2023, 27(1): 68-73. DOI: 10.7619/jcmp.20222801
引用本文: 黄燕华, 邢燕飞, 茅敏华. 肺腺癌后再发小细胞肺癌2例报告[J]. 实用临床医药杂志, 2023, 27(1): 68-73. DOI: 10.7619/jcmp.20222801
HUANG Yanhua, XING Yanfei, MAO Minhua. Small cell lung cancer followed by adenocarcinoma a 2 cases report[J]. Journal of Clinical Medicine in Practice, 2023, 27(1): 68-73. DOI: 10.7619/jcmp.20222801
Citation: HUANG Yanhua, XING Yanfei, MAO Minhua. Small cell lung cancer followed by adenocarcinoma a 2 cases report[J]. Journal of Clinical Medicine in Practice, 2023, 27(1): 68-73. DOI: 10.7619/jcmp.20222801

肺腺癌后再发小细胞肺癌2例报告

Small cell lung cancer followed by adenocarcinoma a 2 cases report

  • 摘要: 腺癌与小细胞癌是肺癌的2种常见病理类型,现报告2例肺腺癌后再发小细胞肺癌(SCLC)患者的临床资料、病理及免疫组织化学、基因检测结果等。1例采用腺癌表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)治疗后发生SCLC转化,另1例为同时性多原发肺癌,结合文献对2例进行比较分析。2例预后均差,但两者的明确诊断及区别还需进一步探索,而神经元特异性烯醇化酶(NSE)对再发SCLC或有预测价值。

     

    Abstract: Adenocarcinoma and small cell carcinoma were two common pathological types of lung cancer. The clinical data, pathological, immunohistochemical and genetic test results of two patients with small cell lung cancer (SCLC) after lung adenocarcinoma were reported. One case of SCLC transformation of epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitor (TKI) after treatment occurred. Another one case was synchronous multiple primary lung cancer, and the two cases were compared based on the literature. The prognosis of the two cases was poor, but the definite diagnosis and difference between them needed further exploration, and neuron specific enolase (NSE) may have predictive value for recurrent SCLC.

     

/

返回文章
返回